Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=265 Colorectal Cancer: Screening vs. Non-Screening
Colorectal Cancer · Screening
Primary: Colorectal Cancer Stage (pTNM) — 46; 85 Participants
N/A N=372 Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Diabetes
Primary: Mean Change in A1C From Baseline to 1 Year — 0.034 percentage
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
Phase 3 N=25 Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Hypoleptinemia · Generalized Lipodystrophy · Partial Lipodystrophy
Primary: Fasting Serum Triglycerides — 203; 304 mg/dL — p=0.2572
Phase 1 N=34 Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
Healthy Subjects
Primary: Time-weighted Averages of Mean Arterial Pressure — 87.40; 87.36 mmHg
N/A N=50 Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant
Function of Renal Transplant
Primary: Calculated Estimated Glomerular Filtration Rate (eGFR) — 67.39; 80.48 ml/min/1.73m2 — p=0.32
Phase 3 N=806 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
Prostatic Neoplasms
Primary: Symptomatic Skeletal Event Free Survival (SSE-FS) — 22.3; 26.0 Months — p=0.2636
Phase 2 N=11 Intravenous Immunoglobulin (IVIG) in Lung Transplantation
Hypogammaglobulinemia · Lung Transplantation
Primary: Number of Clinically Diagnosed Bacterial Infections During the Treatment Period — 3; 1 Infections
N/A N=209 Way to Be Active 2 (Lotteries)
Sedentary Employees
Primary: Proportion of Days a Minimum Activity of 7000 Steps or More is Achieved During Intervention — 0.264; 0.319; 0.290; 0.384 Proportion of participant days
Phase 3 N=200 Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)
Malaria · Human Immunodeficiency Virus
Primary: Number of Participants With Placental Malaria — 3; 6 Participants — p=0.50
Phase 2 N=28 Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
Retinitis Pigmentosa (RP)
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 25; 21; 1 Participants
Phase 2 N=28 A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type
Dementia of Alzheimer's Type
Primary: Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort — 2; 0; 1; 6 Participants
N/A N=25 Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty
Arthroplasty, Knee Replacement · Wound Healing
Primary: Incision Appearance / Scar Cosmesis — 1.3; 2.6; 1.9; 3.3 units on a scale
Phase 2 N=16 Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
Stage II Breast Cancer · Stage IIIA Breast Cancer · Stage IIIB Breast Cancer
Primary: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by…